Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | BACE1 | P56817 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479685 | 0.94 | BCHE (0.41) | BCHEBACE1CA12CA9SLC6A11 | |
| SCHEMBL5981669 | 0.89 | BACE1 (0.42) | BCHEBACE1F2 | |
| SCHEMBL7439104 | 0.81 | BCHE (0.42) | BCHEBACE1 | |
| SCHEMBL2577612 | 0.80 | CA12 (0.39) | CA12CA9F2MEN1MAPT | |
| SCHEMBL13673897 | 0.80 | METAP2 (0.39) | CA12CA9F2MEN1MAPT | |
| SCHEMBL6529408 | 0.79 | F2 (0.41) | BCHEBACE1F2 | |
| SCHEMBL6527555 | 0.79 | BACE1 (0.43) | BCHEBACE1F2KMT2ASMN1; SMN2 | |
| SCHEMBL6526643 | 0.79 | F2 (0.46) | BCHEBACE1F2 | |
| SCHEMBL6527345 | 0.78 | F2 (0.44) | BCHEBACE1F2 | |
| SCHEMBL6527142 | 0.78 | BACE1 (0.43) | BCHEBACE1F2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141609-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6924286-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | disclosed |
| US-6248775-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2001-06-19 | — | — | US | disclosed |
| US-5968942-A | INHIBITORS OF HIV PROTEASE | G. D. SEARLE & CO. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | BCHE 153/4885BACE1 31/4885CA12 1603/4885 |
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | BCHE 175/4885BACE1 18/4885CA12 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.